Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
Kyverna Therapeutics Inc And KYTX Stock Owners Are Encouraged To Participate In A Securities Fraud Investigation Led By The Schall Law Firm
01:45pm, Wednesday, 26'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive
LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive
KYTX Shareholders Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law Firm
02:30pm, Friday, 21'st Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive
LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive
This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a devastating neuroimmunological autoimmune disease KYV-101 is a fully human a
Investors Of KYTX Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law Firm
01:55pm, Wednesday, 19'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive
KYTX Investors Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc By Schall Law Firm
12:30pm, Tuesday, 18'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive
Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option after failure to respond to conventional therapies Significant improvement i
LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive
KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
02:12pm, Friday, 14'th Jun 2024
LOS ANGELES--(BUSINESS WIRE)--KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm.
Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseases Optimal CAR construct design contributing to an acceptable safety profile, and potentia
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
04:05pm, Tuesday, 14'th May 2024
Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology Treated 30 patients cumulatively as of May 14, 2024, including eight patients with myasthenia gravis,
